Q119 Joint Fluid Market: Revenues Down, Pricing Pressures and FDA Scrutiny

Revenues down again, competitive pricing pressures remain, market is under FDA scrutiny

After a sluggish start of the year, the US Joint Fluid market gained steam during the quarter as demand and volumes picked up in several market segments in spite of intense competitive pricing pressures. Revenues were within SmartTRAK’s projected range with a marginal decline of -0.3% YoY according to the recently published SmartTRAK Financial Dashboard.

For Q119, the 3-injection segment accounted for 44.6%  of the US Joint Fluid market, followed by single-injection products at 41.5%, the 5-injection segment at 12.9% and rounding up the market with the 2-injection segment at 1.1%, according to SmartTRAK Financial Dashboard results. The single-injection segment showed good recovery from last year driven by increased adoption of newer products and/or sales expansion measures by some suppliers. The 3-injection segment was down in the low single digits during Q119 owing to continued and fierce pricing competition. The 5-injection segment showed no reprieve from its downward trend, declining...

Among the many topics covered in the Q119 US Joint Fluid Market Recap are:

• Q119 Joint Fluid Market Overview and Highlights
• A Possible Recovery in the Single Injection Segment?
• Overcrowding and Pricing Pressures - The Norm in 3-Injection
• Down She Goes… In the 5-Injection Arena

The 5-injection segment continued to show a declining trend with revenues down -17.0% for Q119 vs the same quarter last year. This segment is strongly impacted by the persisting shift toward lower treatment regimen, suspension of reimbursement and intense competitive pricing from OrthogenRx. Although its pricing model has made OrthogenRx’ Genvisc 850 more attractive, the revenue gain of...

Read the entire Q119 US Joint Fluid Market Recap including news, data, company revenues and analysis*...